Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.
Biomarker and diagnostic research for agammaglobulinemia has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
11 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 3 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05357781](https://clinicaltrials.gov/study/NCT05357781) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:39 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about agammaglobulinemia
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? |
— |
Insel Gruppe AG, University Hospital Bern |
RECRUITING |
[NCT05645107](https://clinicaltrials.gov/study/NCT05645107) | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | PHASE3 | Grifols Therapeutics LLC | RECRUITING |
[NCT06976476](https://clinicaltrials.gov/study/NCT06976476) | Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | PHASE2 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT06954441](https://clinicaltrials.gov/study/NCT06954441) | V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency | PHASE3 | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | RECRUITING |
[NCT05678621](https://clinicaltrials.gov/study/NCT05678621) | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | PHASE2 | Monash University | RECRUITING |
318 publications have been identified in PubMed for agammaglobulinemia. Kisho has analyzed 153 by research type. Research spans Review / Meta-Analysis (26%), Epidemiology / Natural History (24%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 40 | 26% |
Disease patterns and progression | 36 | 24% |
Patient case studies | 29 | 19% |
Laboratory research | 18 | 12% |
Testing and diagnosis research | 12 | 8% |
Clinical study results | 8 | 5% |
Other research | 5 | 3% |
New treatment approaches | 5 | 3% |
Lackey AE (2026). [PMID: 31751055](https://pubmed.ncbi.nlm.nih.gov/31751055/). *Unknown Journal*. [Review / Meta-Analysis]
Gunderman L (2026). [PMID: 41777878](https://pubmed.ncbi.nlm.nih.gov/41777878/). *Front Immunol*. [Case Report / Case Series]
Lewandrowski C (2026). [PMID: 41451820](https://pubmed.ncbi.nlm.nih.gov/41451820/). *Curr Opin Allergy Clin Immunol*. [Review / Meta-Analysis]
Justiz Vaillant AA (2026). [PMID: 29939682](https://pubmed.ncbi.nlm.nih.gov/29939682/). *Unknown Journal*. [Epidemiology / Natural History]
Griffin S (2026). [PMID: 41840412](https://pubmed.ncbi.nlm.nih.gov/41840412/). *Allergy Asthma Proc*. [Epidemiology / Natural History]
Cerono G (2026). [PMID: 40919837](https://pubmed.ncbi.nlm.nih.gov/40919837/). *Ann Neurol*. [Epidemiology / Natural History]
Fallah EA (2026). [PMID: 41385985](https://pubmed.ncbi.nlm.nih.gov/41385985/). *Mult Scler Relat Disord*. [Epidemiology / Natural History]
Soomann M (2026). [PMID: 41177434](https://pubmed.ncbi.nlm.nih.gov/41177434/). *J Allergy Clin Immunol Pract*. [Diagnostic / Biomarker]
Consolini R (2026). [PMID: 42123030](https://pubmed.ncbi.nlm.nih.gov/42123030/). *J Clin Med*. [Review / Meta-Analysis]
von Hundelshausen P (2026). [PMID: 41662453](https://pubmed.ncbi.nlm.nih.gov/41662453/). *Circulation*. [Review / Meta-Analysis]